For more information about the Heart Failure Network trials, please use the links provided. These links will open a new window to the National Institutes of Health website: www.clinicaltrials.gov/
INDIE (Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF
The purpose of INDIE is to test if an investigational study drug, Inorganic Sodium Nitrite Solution (AIR-001) inhaled through a nebulizer (a hand-held breathing device), is safe and can improve the ability to tolerate all forms of physical activity including exercise and thus improve quality of life in people who have chronic heart failure. We anticipate that enrollment will begin in July 2016.
LIFE (Entresto-TM (LCZ696) In Advanced Heart FailurE
The purpose of LIFE is to test whether LCZ696, a newly approved drug for heart failure that combines sacubitril and valsartan, improves symptoms and outcomes in persons with advanced heart failure in comparison to treatment with valsartan alone over 24 weeks. We anticipate that enrollment will begin in 3Q16.
SUBQ-HF (Subcutaneous Furosemide in Acute Decompensated Heart Failure)
The purpose of SUBQ-HF is to evaluate a strategy of early discharge with daily subcutaneous furosemide compared to usual care in patients hospitalized for acute heart failure after initial stabilization. We anticipate that enrollment will begin in 4Q16.
HF/HIV (Characterizing HIV-related Diastolic Dysfunction: A Cross-Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network)
The overarching objective of the HF/HIV trial is to study the determinants, mechanisms, and consequences of diastolic dysfunction in HIV infected individuals. We anticipate that enrollment will begin in 4Q16.